- Home
- KODK vs XNCR Comparison
KODK vs XNCR Comparison
Compare KODK & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KODK
- XNCR
- Stock Information
- Founded
- KODK 1880
- XNCR 1997
- Country
- KODK United States
- XNCR United States
- Employees
- KODK N/A
- XNCR N/A
- Industry
- KODK Business Services
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- KODK Consumer Discretionary
- XNCR Health Care
- Exchange
- KODK Nasdaq
- XNCR Nasdaq
- Market Cap
- KODK 476.6M
- XNCR 547.8M
- IPO Year
- KODK N/A
- XNCR 2013
- Fundamental
- Price
- KODK $6.62
- XNCR $14.77
- Analyst Decision
- KODK
- XNCR Buy
- Analyst Count
- KODK 0
- XNCR 11
- Target Price
- KODK N/A
- XNCR $22.20
- AVG Volume (30 Days)
- KODK 1.2M
- XNCR 1.3M
- Earning Date
- KODK 11-11-2025
- XNCR 11-05-2025
- Dividend Yield
- KODK N/A
- XNCR N/A
- EPS Growth
- KODK N/A
- XNCR N/A
- EPS
- KODK N/A
- XNCR N/A
- Revenue
- KODK $1,037,000,000.00
- XNCR $146,929,000.00
- Revenue This Year
- KODK N/A
- XNCR $23.31
- Revenue Next Year
- KODK N/A
- XNCR N/A
- P/E Ratio
- KODK N/A
- XNCR N/A
- Revenue Growth
- KODK N/A
- XNCR N/A
- 52 Week Low
- KODK $4.26
- XNCR $6.92
- 52 Week High
- KODK $8.24
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- KODK 53.16
- XNCR 73.35
- Support Level
- KODK $6.33
- XNCR $11.17
- Resistance Level
- KODK $7.18
- XNCR $15.37
- Average True Range (ATR)
- KODK 0.31
- XNCR 0.90
- MACD
- KODK -0.00
- XNCR 0.19
- Stochastic Oscillator
- KODK 41.75
- XNCR 84.29
About KODK Eastman Kodak Company Common New
Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.